top of page

MIRaCLe
Translational Imaging Biomarkers of CNS Disease

Biomarkers are increasingly important in the diagnosis of disease and the application of precision medicine.

Positron Emission Tomography (PET) is the most sensitive imaging technique that can be applied in humans. PET can provide fully quantitative Imaging Biomarkers for CNS disease for a range of molecular targets.

Miracle targeted molecule to bedside chain.png

Development of a Molecular Imaging Biomarker

The development of a PET imaging biomarker is analogous to the development of a drug, and runs through the following steps:

  • Target identification 

  • Lead compound development

  • In vitro and on vivo assessment in preclinical models

    • Brain penetrance

    • Selectivity

    • Specificity

    • Metabolism

    • Quantitation

  • First-in-human studies

We offer support for all phases of CNS imaging biomarker development.

miracle clinical research.jpg

Development and validation: a targeted ‘Molecule to Bedside’ chain

MIRaCLe integrates academic and clinical leads in radiopharmacy and nuclear medicine, with supporting preclinical and clinical infrastructure. As such, we apply multidisciplinary expertise with state-of-the-art infrastructure to offer translational studies for drug development, clinical trials and fundamental research studies, particularly for CNS targets.

The experts

The Molecular Imaging Research and Clinic Leuven (MIRaCLe) integrates tracer development through preclinical validation to GMP production and first-in man/clinical research studies at KU Leuven and UZ Leuven.

KU Leuven logo wit.png
UZ Leuven negatief.png
Logo - MIRaCLe - 1.jpg

Explore our other spearpoint technologies

FBI logo transparant_edited.png

We are funded by FWO
FWO I000123N

 

Christopher Cawthorne
Flanders BioImaging Co-ordinator

O&N I Herestraat 49 - box 505
3000 Leuven
Belgium​​​

Euro-Bioimaging-horizontal-RGB_edited.jpg
KU Leuven logo wit.png
UA-hor-1-nl-white.png
uhasselt-liggend-wit.png
VIB logo wit.png

© 2023 Flanders BioImaging

bottom of page